Merck's Nigeria test shows off anti-counterfeiting tech

Nigeria has gone far beyond conducting tests of drug anti-counterfeiting technology from Sproxil with Merck, as reported incorrectly last week. Sproxil launched its service in February in Nigeria, according to an Indian press report. The drug giant pays to have Sproxil's package labels put on its diabetes drug.

In the program, which has the support of Nigerian drug officials, drug takers use a crowdsourcing technique to ferret out the fakes. Consumers scratch a sticker on the drug package and then send a text message containing the security code revealed to a toll-free number. The ID code is forwarded to a server for verification, and the drug company feeds data to government officials, who pursue the counterfeiters.

Ghana-born Ashifi Gogo, Sproxil's founder, says the anti-counterfeiting technology company has received orders for four million labels for just one of Merck's product lines.

The order was preceded by a 100-day pilot that ran through April. In the pilot, about 735,000 Merck drug packs, distributed by Nigerian company Biofem, were checked. The pilot ran at 125 pharmacies in three Nigerian cities. Sproxil's system handled some 23,000 text messages from 6,800 users with just two recorded errors. And in May, the system identified counterfeiting activity in the field, Sproxil says.

- see the article
- here's a link to get pilot results

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.